83
Participants
Start Date
May 20, 2022
Primary Completion Date
December 17, 2024
Study Completion Date
December 17, 2024
Pemigatinib
13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza, Torino
Northwell Health, Lake Success
Chu Hopital de La Timone, Marseille
University of Pittsburgh Medical Center Health System, Pittsburgh
Ico Girona Hospital Universitari de Girona Dr Josep Trueta, Girona
University of Pennsylvania Hospital, Philadelphia
Irccs Istituto Clinico Humanitas, Rozzano
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan
Wake Forest Baptist Health, Winston-Salem
East Carolina University, Greenville
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario Ramon Y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Hm Sanchinarro, Madrid
Clinica Universidad de Navarra (Cun), Pamplona
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse
Baptist Md Anderson Cancer Center, Jacksonville
Orlando Health Cancer Institute Downtown Orlando, Orlando
Miami Cancer Institute, Miami
H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa
Iov - Istituto Oncologico Veneto Irccs, Padua
Tennessee Oncology, Nashville
Tennessee Oncology, Chattanooga
Ospedale Bellaria, Bologna
Hospital Universitario Virgen Del Rocio, Seville
Cleveland Clinic Foundation, Cleveland
UC Health At Cincinnati Va Medical Center, Cincinnati
Hospital General Universitario de Valencia, Valencia
University of Iowa Hospital and Clinics, Iowa City
Universitatsklinikum Bonn Aoer, Bonn
University of Minnesota Health Clinics and Surgery Center, Minneapolis
Chru de Lille Hopital Claude Huriez, Lille
Klinikum Der Johann Wolfgang Goethe University, Frankfurt
University of Illinois Hospital & Health Sciences System, Chicago
Universitaetsklinikum Heidelberg, Heidelberg
University Medical Center New Orleans, New Orleans
University Hospital Tuebingen, Tübingen
Hospital Universitaire Pitie-Salpetriere, Paris
Baylor University Medical Center, Dallas
Houston Methodist Hospital, Houston
A.S.L. Napoli 1 Centro Ospedale Del Mare, Ponticelli
Huntsman Cancer Institute, Salt Lake City
Usc Norris Comprehensive Cancer Center, Los Angeles
Valkyrie Clinical Trials, Beverly Hills
Providence St Joseph Hospital Orange Center For Cancer Prevention and Treatment, Santa Monica
City of Hope National Medical Center, Duarte
Sharp Memorial Hospital, San Diego
Providence Medical Foundation, Fullerton
University of California San Francisco, San Francisco
Stanford Neuroscience Health Center, Sacramento
Fred Hutchinson Cancer Research Center, Seattle
Yale Cancer Center, New Haven
Aalborg Universitets Hospital, Aalborg
Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen
Odense University Hospital, Odense C
University of Tokyo Hospital, Bunkyō City
National Cancer Center Hospital, Chūōku
Kyushu University Hospital, Fukuoka
Kyoto University Hospital, Kyoto
Nagoya University Hospital, Nagoya
Tohoku University Hospital, Sendai
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
Erasmus Mc Cancer Institute, Rotterdam
Hospital Del Mar, Barcelona
Hospital General Universitario Vall D Hebron, Barcelona
Hospital Clinic Barcelona Main, Barcelona
Hospital de La Santa Creu I Sant Pau, Barcelona
Ico Institut Catala D Oncologia, L'Hospitalet de Llobregat
Hospital General de Catalunya, Sant Cugat del Vallès
Addenbrooke'S Hospital, Cambridge
Velindre Cancer Centre, Cardiff
St James'S University Hospital, Leeds
Guys Hospital, London
The Royal Marsden Nhs Foundation Trust - Sutton, London
The Royal Marsden Nhs Foundation Trust - Chelsea, London
The Christie Nhs Foundation Trust Uk, Manchester
The Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
Lead Sponsor
Incyte Corporation
INDUSTRY